Adalgeir Arason

Adalgeir Arason

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1995 in Nature
Verified
Journal Article
Closed access
RWRichard Wooster
Richard Wooster
GBGraham Bignell
Graham Bignell
JLJonathan Lancaster
Jonathan Lancaster
SSSally Swift
Sally Swift
SSSheila Seal
Sheila Seal
MSMichael R. Stratton
Michael R. Stratton

1 December 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
AAAntonis C. Antoniou
Antonis C. Antoniou
OSOlga M. Sinilnikova
Olga M. Sinilnikova
JSJacques Simard
Jacques Simard
MLMélanie Léoné
Mélanie Léoné
MDMartine Dumont
Martine Dumont
GCGeorgia Chenevix-Trench
Georgia Chenevix-Trench

7 January 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GCGEMO Study Collaborators
GEMO Study Collaborators
LFLaura Fachal
Laura Fachal
ECEmbrace Collaborators
Embrace Collaborators
KIKConFab Investigators
KConFab Investigators
HIHEBON Investigators
HEBON Investigators
ADAlison M. Dunning
Alison M. Dunning

24 June 2010 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
Göran JönssonGöran Jönsson
Göran Jönsson
JSJohan Staaf
Johan Staaf
JVJohan Vallon-Christersson
Johan Vallon-Christersson
MRMarkus Ringnér
Markus Ringnér
KHKarolina Holm
Karolina Holm
ÅBÅke Borg
Åke Borg
Introduction: Breast cancer is a profoundly heterogeneous disease with respect to biologic and clinical behavior. Gene-expression profiling has been used to dissect this complexity and to stratify tumors into intrinsic gene-expression subtypes, associated with distinct biology, patient outcome, and genomic alterations. Additionally, breast tumors occurring in individuals with germline BRCA1 or BRCA2 mutations typically fall into distinct subtypes. Methods: We applied global DNA copy number and gene-expression profiling in 359 breast tumors. All tumors were classified according to intrinsic gene-expression subtypes and included cases from genetically predisposed women. The Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm was used to identify significant DNA copy-number aberrations and genomic subgroups of breast cancer. Results: We identified 31 genomic regions that were highly amplified in > 1% of the 359 breast tumors. Several amplicons were found to co-occur, the 8p12 and 11q13.3 regions being the most frequent combination besides amplicons on the same chromosomal arm. Unsupervised hierarchical clustering with 133 significant GISTIC regions revealed six genomic subtypes, termed 17q12, basal-complex, luminal-simple, luminal-complex, amplifier, and mixed subtypes. Four of them had striking similarity to intrinsic gene-expression subtypes and showed associations to conventional tumor biomarkers and clinical outcome. However, luminal A-classified tumors were distributed in two main genomic subtypes, luminal-simple and luminal-complex, the former group having a better prognosis, whereas the latter group included also luminal B and the majority of BRCA2-mutated tumors. The basal-complex subtype displayed extensive genomic homogeneity and harbored the majority of BRCA1-mutated tumors. The 17q12 subtype comprised mostly HER2-amplified and HER2-enriched subtype tumors and had the worst prognosis. The amplifier and mixed subtypes contained tumors from all gene-expression subtypes, the former being enriched for 8p12-amplified cases, whereas the mixed subtype included many tumors with predominantly DNA copy-number losses and poor prognosis. Conclusions: Global DNA copy-number analysis integrated with gene-expression data can be used to dissect the complexity of breast cancer. This revealed six genomic subtypes with different clinical behavior and a striking concordance to the intrinsic subtypes. These genomic subtypes may prove useful for understanding the mechanisms of tumor development and for prognostic and treatment prediction purposes.

6 May 2010 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
JSJohan Staaf
Johan Staaf
Göran JönssonGöran Jönsson
Göran Jönsson
MRMarkus Ringnér
Markus Ringnér
JVJohan Vallon-Christersson
Johan Vallon-Christersson
DGDorthe Grabau
Dorthe Grabau
ÅBÅke Borg
Åke Borg
Introduction: HER2 gene amplification and protein overexpression (HER2+) define a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. Although gene expression profiling has identified an ERBB2 molecular subtype of breast cancer, it is clear that HER2+ tumors reside in all molecular subtypes and represent a genomically and biologically heterogeneous group, needed to be further characterized in large sample sets. Methods: Genome-wide DNA copy number profiling, using bacterial artificial chromosome (BAC) array comparative genomic hybridization (aCGH), and global gene expression profiling were performed on 200 and 87 HER2+ tumors, respectively. Genomic Identification of Significant Targets in Cancer (GISTIC) was used to identify significant copy number alterations (CNAs) in HER2+ tumors, which were related to a set of 554 non-HER2 amplified (HER2-) breast tumors. High-resolution oligonucleotide aCGH was used to delineate the 17q12-q21 region in high detail. Results: The HER2-amplicon was narrowed to an 85.92 kbp region including the TCAP, PNMT, PERLD1, HER2, C17orf37 and GRB7 genes, and higher HER2 copy numbers indicated worse prognosis. In 31% of HER2+ tumors the amplicon extended to TOP2A, defining a subgroup of HER2+ breast cancer associated with estrogen receptor-positive status and with a trend of better survival than HER2+ breast cancers with deleted (18%) or neutral TOP2A (51%). HER2+ tumors were clearly distinguished from HER2- tumors by the presence of recurrent high-level amplifications and firestorm patterns on chromosome 17q. While there was no significant difference between HER2+ and HER2- tumors regarding the incidence of other recurrent high-level amplifications, differences in the co-amplification pattern were observed, as shown by the almost mutually exclusive occurrence of 8p12, 11q13 and 20q13 amplification in HER2+ tumors. GISTIC analysis identified 117 significant CNAs across all autosomes. Supervised analyses revealed: (1) significant CNAs separating HER2+ tumors stratified by clinical variables, and (2) CNAs separating HER2+ from HER2- tumors. Conclusions: We have performed a comprehensive survey of CNAs in HER2+ breast tumors, pinpointing significant genomic alterations including both known and potentially novel therapeutic targets. Our analysis sheds further light on the genomically complex and heterogeneous nature of HER2+ tumors in relation to other subgroups of breast cancer.

15 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFManuel A Ferreira
Manuel A Ferreira
EGEric Gamazon
Eric Gamazon
FAFares Al-Ejeh
Fares Al-Ejeh
KAKristiina Aittomäki
Kristiina Aittomäki
IAIrene L Andrulis
Irene L Andrulis
GCGeorgia Chenevix-Trench
Georgia Chenevix-Trench
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into the etiology of breast cancer.